Table 1.

Baseline patient characteristics of individuals with dcSSc. Values are n (%) unless otherwise specified.

Characteristics	Imatinib, n = 26	Nilotinib, n = 8
Age, yrs, mean (range)	48.6 (18–71)	47.9 (18–69)
Women	21 (80.8)	6 (75)
Race
White	22 (84.6)	5 (62.5)
Hispanic	2 (7.7)	0
African American	0 (0)	3 (37.5)
Undefined	2 (7.7)	0 (0)
Disease duration, yrs, mean (range)^*	3.3 (0.33–8)	0.75 (0.42–2)
mRSS, median (range)	26.5 (19–46)	27 (22–44)
Scl-70+	7 (28)	2 (25)
ANA+	16 (83.3)	7 (100)
ACA+	0 (0)	0 (0)
RNA Pol III^**	1 (16.7)	5 (62.5)
ILD involvement	13 (50)	2 (25)
FVC % predicted, mean (range)	84 (45–128)	77 (58–98)
DLCO % predicted, mean (range)	79 (45–127)	71 (55–85)

↵* Since first non-Raynaud symptom of SSc.
↵** Seven patients in the imatinib trial were tested for RNA Pol III antibodies. mRSS: modified Rodnan skin score; ANA: antinuclear antibody; ACA: anticentromere antibodies; ILD: interstitial lung disease; FVC: forced vital capacity.